2-chloro-D-glucose

2-chloro-D-glucose (2-CG) is a halogenated analog of 2-deoxy-D-glucose (2-DG) that was synthesized and evaluated as a potential inhibitor of glycolysis in cancer cells. Developed at the UT MD Anderson Cancer Center, it was part of a study investigating 2-deoxy-2-halo-D-glucose derivatives for the treatment of pancreatic ductal adenocarcinoma (PDAC), a highly glycolytic and hypoxic tumor type. In comparative in vitro studies, 2-CG demonstrated significantly lower potency in inhibiting the extracellular acidification rate (ECAR) and reducing cellular ATP levels compared to 2-fluoro-D-glucose (2-FG) and 2,2-difluoro-D-glucose (2,2-diFG). Consequently, it is primarily used as a research tool to study the structure-activity relationships of glucose analogs in metabolic inhibition.

Other names

2-chloro-2-deoxy-D-glucose